G0S2

Summary

G0S2 (G0/G1 switch 2, HGNC:30229) is a protein-coding gene on chromosome 1q32.2, encoding G0/G1 switch protein 2 (P27469). Promotes apoptosis by binding to BCL2, hence preventing the formation of protective BCL2-BAX heterodimers.

Involved in extrinsic apoptotic signaling pathway and positive regulation of extrinsic apoptotic signaling pathway. Located in mitochondrion.

Source: NCBI Gene 50486 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 11 total
• MANE Select transcript: NM_015714

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30229
Approved symbol	G0S2
Name	G0/G1 switch 2
Location	1q32.2
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000123689
Ensembl biotype	protein_coding
OMIM	614447
Entrez	50486

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 4 protein_coding

ENST00000367029, ENST00000891678, ENST00000891679, ENST00000959384

RefSeq mRNA: 1 — MANE Select: NM_015714 NM_015714

CCDS: CCDS1488

Canonical transcript exons

ENST00000367029 — 2 exons

Exon	Start	End
ENSE00001010307	209675412	209675549
ENSE00001443289	209675653	209676390

Expression profiles

Bgee: expression breadth ubiquitous, 277 present calls, max score 99.65.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 232.9790 / max 39342.2718, expressed in 1294 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
8338	227.6198	1288
8342	1.6548	290
8344	1.0139	220
8345	0.7462	201
8343	0.6853	172
8340	0.6311	175
8341	0.3472	129
8339	0.2808	104

Top tissues by expression

291 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
vena cava	UBERON:0004087	99.65	gold quality
synovial joint	UBERON:0002217	99.53	gold quality
periodontal ligament	UBERON:0008266	99.53	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	99.22	gold quality
adipose tissue	UBERON:0001013	99.12	gold quality
pericardium	UBERON:0002407	99.11	gold quality
adipose tissue of abdominal region	UBERON:0007808	99.04	gold quality
omental fat pad	UBERON:0010414	98.99	gold quality
peritoneum	UBERON:0002358	98.96	gold quality
subcutaneous adipose tissue	UBERON:0002190	98.87	gold quality
cartilage tissue	UBERON:0002418	98.84	gold quality
apex of heart	UBERON:0002098	98.68	gold quality
connective tissue	UBERON:0002384	98.65	gold quality
right lobe of liver	UBERON:0001114	98.21	gold quality
triceps brachii	UBERON:0001509	98.11	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	98.09	gold quality
left adrenal gland cortex	UBERON:0035825	98.03	gold quality
vastus lateralis	UBERON:0001379	97.99	gold quality
left adrenal gland	UBERON:0001234	97.91	gold quality
renal medulla	UBERON:0000362	97.75	gold quality
diaphragm	UBERON:0001103	97.72	gold quality
adrenal cortex	UBERON:0001235	97.72	gold quality
quadriceps femoris	UBERON:0001377	97.40	gold quality
biceps brachii	UBERON:0001507	97.29	gold quality
right adrenal gland	UBERON:0001233	97.24	gold quality
body of tongue	UBERON:0011876	97.24	gold quality
skeletal muscle tissue	UBERON:0001134	97.12	gold quality
cardiac atrium	UBERON:0002081	96.95	gold quality
right atrium auricular region	UBERON:0006631	96.93	gold quality
heart left ventricle	UBERON:0002084	96.86	gold quality

Single-cell (SCXA)

Detected in 15 experiment(s), a significant marker in 13.

Experiment	Marker?	Max mean expression
E-MTAB-6678	yes	10391.48
E-MTAB-9221	yes	9362.11
E-MTAB-9801	yes	8544.06
E-HCAD-4	yes	198.40
E-MTAB-8142	yes	89.74
E-HCAD-1	yes	85.26
E-MTAB-9467	yes	37.45
E-CURD-46	yes	31.86
E-HCAD-10	yes	22.50
E-CURD-114	yes	20.20
E-MTAB-6701	yes	19.01
E-MTAB-10553	yes	5.31
E-MTAB-8559	no	1739.29
E-MTAB-7381	no	1104.09
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): NCOR1, NFKB, PPARA, RARA, RELA

miRNA regulators (miRDB)

51 targeting G0S2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-223-3P	99.99	70.14	1140
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-545-3P	99.95	70.74	2783
HSA-MIR-128-3P	99.95	71.17	2484
HSA-MIR-216A-3P	99.95	71.19	2505
HSA-MIR-205-3P	99.92	69.92	3165
HSA-MIR-497-5P	99.92	71.83	2674
HSA-MIR-454-3P	99.91	74.01	1925
HSA-MIR-3666	99.90	73.24	1833
HSA-MIR-130A-3P	99.90	73.31	1861
HSA-MIR-130B-3P	99.90	73.27	1850
HSA-MIR-301A-3P	99.90	73.15	1839
HSA-MIR-301B-3P	99.90	73.19	1836
HSA-MIR-4295	99.90	73.11	1838
HSA-MIR-15A-5P	99.90	72.80	2787
HSA-MIR-15B-5P	99.90	72.78	2798
HSA-MIR-16-5P	99.90	72.80	2780
HSA-MIR-195-5P	99.90	72.81	2805
HSA-MIR-548E-5P	99.89	72.73	4486
HSA-MIR-6838-5P	99.89	71.94	2690
HSA-MIR-424-5P	99.89	71.90	2641
HSA-MIR-3681-3P	99.88	70.46	2254
HSA-MIR-4698	99.84	71.41	4303

Literature-anchored findings (GeneRIF, showing 27)

• A novel putative target gene of PPARalpha, G0S2 (G0/G1 switch gene 2) was identified and characterized. (PMID:16086669)
• G0S2 is an all-trans-retinoic acid target gene (PMID:18636162)
• G0S2 encodes a mitochondrial protein that specifically interacts with Bcl-2 and promotes apoptosis by preventing the formation of protective Bcl-2/Bax heterodimers (PMID:19706769)
• DNA methylation of G0S2 can be an important biomarker for squamous lung cancer. (PMID:19816938)
• mRNA expression of G0S2 was regulated mainly by DNA methylation in squamous lung cancer cell lines. (PMID:19878646)
• findings are compatible with the notion that the ATGL-G0S2 complex is an important long-term regulator of lipolysis under physiological conditions such as fasting in humans (PMID:21613358)
• Reduced mRNA and protein content of Plin and G0S2 and borderline increased ATGL protein in sc adipose tissue from poorly controlled type 2 diabetic subjects. (PMID:22535977)
• Gene expression profiles showed that G0/G1 switch 2 was up-regulated in epidermolysis bullosa subtypes. (PMID:22716248)
• Data indicate that downregulation of G0S2 in adipose tissue could represent one of the underlying causes leading to increased lipolysis in the insulin-resistant state. (PMID:22891293)
• This linked G0S2 subcellular localization to G0S2 transcriptional repression. The potential mechanisms responsible for this G0S2 repression are examined. (PMID:23546556)
• reelin expression is altered by Abeta leading to impaired reelin signaling. (PMID:23951308)
• A new mechanism that controls proliferation in K562 cells, suggesting a possible tumor suppressor function for G0S2 in leukemia cells. (PMID:24183236)
• Data indicate that the peptide corresponding to residues Lys-20 to Ala-52 from G0S2 Inhibits ATGL in the nanomolar range. (PMID:25258314)
• Results indicate that G0S2 acts as a prosurvival molecule in endothelial cells. (PMID:25588877)
• Data indicate that a tumor suppressor mechanism by which G0/G1 switch gene 2 product (G0S2) directly inhibits activity of a key intracellular adipose triglyceride lipase (ATGL). (PMID:26318046)
• differences in G0S2 expression may explain depot-specific and obesity-associated differences in lipolysis on the molecular level (PMID:26707160)
• PML/RARalpha synergizes with C/EBPepsilon to reactivate the C/EBPepsilon target G0S2, thereby contributing to All-trans retinoic acid -mediated acute promyelocytic leukemia differentiation and potentially, clinical remission. (PMID:27605212)
• G0S2 functions as a master regulator of tissue-specific balance of TG storage vs. mobilization, partitioning of metabolic fuels between adipose and liver, and the whole-body adaptive energy response. (PMID:28645852)
• ER+ breast cancer cells with restored G0S2 expression had a relative increased sensitivity to tamoxifen (PMID:28910567)
• Palmitate can induce lipid accumulation in HepG2 cells by activating C/EBPbeta-mediated G0S2 expression. (PMID:29209111)
• G0S2 hypermethylation is a hallmark of rapidly recurrent or fatal ACC, amenable to targeted assessment using routine molecular diagnostics. Assessing G0S2 methylation is straightforward, feasible for clinical decision-making, and will enable the direction of efficacious adjuvant therapies for patients with aggressive ACC. (PMID:30770352)
• In addition to its role as a lipolytic inhibitor, G0S2 is capable of directly promoting TG synthesis by acting as a lipid-synthesizing enzyme. (PMID:30802154)
• We conclude that the RNF126/BAG6 complex contributes to G0S2 degradation and that interventions to prevent G0S2 degradation may offer a therapeutic strategy for managing ischemic diseases. (PMID:31371451)
• An epigenome-wide association study of posttraumatic stress disorder in US veterans implicates several new DNA methylation loci. (PMID:32171335)
• Low G0S2 gene expression levels in peripheral blood may be a genetic marker of acute myocardial infarction in patients with stable coronary atherosclerotic disease: A retrospective clinical study. (PMID:33545927)
• Gastric Cancer Growth Modulated by circSNTB2/miR-6938-5p/G0S2 and PDCD4. (PMID:36366842)
• Loss of G0/G1 switch gene 2 (G0S2) promotes disease progression and drug resistance in chronic myeloid leukaemia (CML) by disrupting glycerophospholipid metabolism. (PMID:36536477)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	g0s2	ENSDARG00000078859
mus_musculus	G0s2	ENSMUSG00000009633
rattus_norvegicus	G0s2	ENSRNOG00000006019

Protein

Protein identifiers

G0/G1 switch protein 2 — P27469 (reviewed: P27469)

Alternative names: G0/G1 switch regulatory protein 2, Putative lymphocyte G0/G1 switch gene

All UniProt accessions (1): P27469

UniProt curated annotations — full annotation on UniProt →

Function. Promotes apoptosis by binding to BCL2, hence preventing the formation of protective BCL2-BAX heterodimers.

Subunit / interactions. Directly interacts with BCL2; this interaction prevents the formation of the anti-apoptotic BAX-BCL2 complex.

Subcellular location. Mitochondrion.

Tissue specificity. Widely expressed with highest levels in peripheral blood, skeletal muscle and heart, followed by kidney and liver.

Induction. Induced by TNF through the activation of the NFKB pathway.

RefSeq proteins (1): NP_056529* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR016821	G0S2	Family

Pfam: PF15103

UniProt features (16 total): mutagenesis site 14, chain 1, region of interest 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P27469-F1	76.60	0.23

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Mutagenesis-validated functional residues (14):

Position	Phenotype
50	reduced bcl2-binding; when associated with a-51.
51	reduced bcl2-binding; when associated with a-50.
54	reduced bcl2-binding; when associated with a-55.
55	reduced bcl2-binding; when associated with a-54.
57	reduced bcl2-binding and reduced pro-apoptotic activity; when associated with a-58. no effect on mitochondrial localizat
58	reduced bcl2-binding and reduced pro-apoptotic activity; when associated with a-57. no effect on mitochondrial localizat
35	no effect on bcl2-binding; when associated with a-36.
36	no effect on bcl2-binding; when associated with a-35.
38	no effect on bcl2-binding; when associated with a-39.
39	no effect on bcl2-binding; when associated with a-38.
43	no effect on bcl2-binding; when associated with a-44.
44	no effect on bcl2-binding; when associated with a-43.
45	no effect on bcl2-binding; when associated with a-46.
46	no effect on bcl2-binding; when associated with a-45.

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-1989781	PPARA activates gene expression

MSigDB gene sets: 361 (showing top): TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_MONOCYTE_UP, TSUNODA_CISPLATIN_RESISTANCE_UP, MCLACHLAN_DENTAL_CARIES_UP, TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497, MCBRYAN_PUBERTAL_TGFB1_TARGETS_UP, GOBP_EXTRINSIC_APOPTOTIC_SIGNALING_PATHWAY, TGACCTY_ERR1_Q2, KANNAN_TP53_TARGETS_DN, ZHAN_MULTIPLE_MYELOMA_CD1_UP, COUP_01, BILD_HRAS_ONCOGENIC_SIGNATURE, CEBP_Q2, GOBP_APOPTOTIC_SIGNALING_PATHWAY, RHEIN_ALL_GLUCOCORTICOID_THERAPY_UP, GOBP_REGULATION_OF_EXTRINSIC_APOPTOTIC_SIGNALING_PATHWAY

GO Biological Process (4): extrinsic apoptotic signaling pathway (GO:0097191), positive regulation of cold-induced thermogenesis (GO:0120162), positive regulation of extrinsic apoptotic signaling pathway (GO:2001238), apoptotic process (GO:0006915)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (2): mitochondrion (GO:0005739), lipid droplet (GO:0005811)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Regulation of lipid metabolism by PPARalpha	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
apoptotic signaling pathway	2
cell surface receptor signaling pathway	1
positive regulation of multicellular organismal process	1
cold-induced thermogenesis	1
regulation of cold-induced thermogenesis	1
extrinsic apoptotic signaling pathway	1
positive regulation of apoptotic signaling pathway	1
regulation of extrinsic apoptotic signaling pathway	1
programmed cell death	1
execution phase of apoptosis	1
binding	1
cytoplasm	1
intracellular membrane-bounded organelle	1
intracellular membraneless organelle	1

Protein interactions and networks

STRING

1082 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
G0S2	PNPLA2	Q96AD5	886
G0S2	ABHD5	Q8WTS1	736
G0S2	BCL2	P10415	732
G0S2	LIPE	Q05469	589
G0S2	CIDEC	Q96AQ7	531
G0S2	PLIN1	O60240	529
G0S2	HILPDA	Q9Y5L2	525
G0S2	MGLL	Q99685	487
G0S2	NUCLEOLIN	P19338	449
G0S2	PLIN2	Q99541	443
G0S2	GADD45G	O95257	436
G0S2	FITM1	A5D6W6	419
G0S2	VNN1	O95497	414
G0S2	LY6D	Q14210	409
G0S2	PCTP	Q9UKL6	408

IntAct

10 interactions, top by confidence:

A	B	Type	Score
BCL2L2	G0S2	psi-mi:“MI:0915”(physical association)	0.560
BCL2L1	G0S2	psi-mi:“MI:0915”(physical association)	0.560
G0S2	BCL2L2	psi-mi:“MI:0915”(physical association)	0.560
G0S2	BCL2L1	psi-mi:“MI:0915”(physical association)	0.560
G0S2	RPL30	psi-mi:“MI:0915”(physical association)	0.370
G0S2	OIP5	psi-mi:“MI:0914”(association)	0.350
G0S2	UGT8	psi-mi:“MI:0914”(association)	0.350

BioGRID (22): PNPLA2 (Affinity Capture-Western), BCL2L2 (Two-hybrid), BCL2L1 (Two-hybrid), G0S2 (Phenotypic Suppression), G0S2 (Biochemical Activity), MTHFR (Affinity Capture-MS), OIP5 (Affinity Capture-MS), RNF20 (Affinity Capture-MS), SUSD1 (Affinity Capture-MS), PNPLA2 (Affinity Capture-MS), MIS18A (Affinity Capture-MS), USP16 (Affinity Capture-MS), FERMT2 (Affinity Capture-MS), NEBL (Affinity Capture-MS), ANKRD54 (Affinity Capture-MS)

ESM2 similar proteins: A0A1B0GUI7, A0A1D8PTI7, A0A1L8H579, A0A1L8HCK2, A0A1W2PPG7, A1DL98, A1X8D9, A6NF36, P0DMK0, P0DUP1, P20290, P24051, P27469, P31790, P33716, P36826, P55833, P57076, P68968, P68969, P82014, Q28GG3, Q28HY7, Q2U6N1, Q3KPU7, Q3T0B7, Q4V853, Q58CS6, Q5RA87, Q5RGZ1, Q5U3Z0, Q5XIC3, Q5YKI7, Q63603, Q64152, Q66KZ1, Q6AX78, Q6DRC3, Q6PK57, Q6ZWY3

Diamond homologs: P27469, Q5M840, Q61585

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

11 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	9
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

70 predictions. Top by Δscore:

Variant	Effect	Δscore
1:209675545:CTAAG:C	donor_loss	1.0000
1:209675546:TAAGG:T	donor_loss	1.0000
1:209675548:AGG:A	donor_loss	1.0000
1:209675549:GGTAG:G	donor_loss	1.0000
1:209675648:TGCA:T	acceptor_loss	1.0000
1:209675649:GCA:G	acceptor_loss	1.0000
1:209675651:A:AG	acceptor_gain	1.0000
1:209675651:A:AT	acceptor_loss	1.0000
1:209675652:G:GG	acceptor_gain	1.0000
1:209675652:G:GT	acceptor_loss	1.0000
1:209675652:GGTC:G	acceptor_gain	1.0000
1:209675550:GT:G	donor_loss	0.9900
1:209675651:AG:A	acceptor_gain	0.9900
1:209675652:GG:G	acceptor_gain	0.9900
1:209675652:GGT:G	acceptor_gain	0.9900
1:209675652:GGTCA:G	acceptor_gain	0.9900
1:209675550:G:T	donor_gain	0.9800
1:209675648:T:A	acceptor_gain	0.9800
1:209675639:T:A	acceptor_gain	0.9700
1:209675545:C:CG	donor_gain	0.9500
1:209675550:G:GG	donor_gain	0.9100
1:209675545:C:G	donor_gain	0.8600
1:209675475:C:A	donor_gain	0.8000
1:209675541:GCCAC:G	donor_gain	0.7500
1:209675548:AG:A	donor_gain	0.7300
1:209675549:GG:G	donor_gain	0.7300
1:209675636:T:A	acceptor_gain	0.6900
1:209675759:GCT:G	donor_gain	0.6200
1:209675648:TGCAG:T	acceptor_gain	0.5900
1:209675649:GCAGG:G	acceptor_gain	0.5900

AlphaMissense

653 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:209675775:A:C	S31R	0.983
1:209675777:C:A	S31R	0.983
1:209675777:C:G	S31R	0.983
1:209675794:G:A	G37D	0.964
1:209675772:G:C	G30R	0.955
1:209675773:G:A	G30D	0.950
1:209675785:C:A	A34D	0.949
1:209675793:G:C	G37R	0.946
1:209675782:T:G	L33R	0.896
1:209675763:T:G	Y27D	0.882
1:209675716:C:A	A11D	0.879
1:209675809:T:C	L42P	0.861
1:209675788:T:G	L35R	0.848
1:209675707:T:C	I8T	0.835
1:209675767:T:A	V28E	0.831
1:209675782:T:A	L33Q	0.831
1:209675809:T:G	L42R	0.831
1:209675788:T:A	L35H	0.823
1:209675805:G:C	G41R	0.823
1:209675779:T:A	V32E	0.784
1:209675704:T:C	L7P	0.782
1:209675823:T:C	C47R	0.781
1:209675797:T:A	V38E	0.770
1:209675763:T:A	Y27N	0.765
1:209675803:T:A	L40H	0.762
1:209675800:T:A	V39E	0.759
1:209675809:T:A	L42Q	0.759
1:209675776:G:A	S31N	0.751
1:209675821:T:A	V46E	0.751
1:209675759:G:C	K25N	0.742

dbSNP variants (sampled 300 via entrez): RS1000897849 (1:209674777 A>G), RS1001206405 (1:209676423 G>A), RS1001703605 (1:209676732 C>A,T), RS1001861463 (1:209674961 C>T), RS1002313207 (1:209675450 G>T), RS1002503624 (1:209674702 TCTCTCTCTCA>T), RS1002667384 (1:209675326 G>A), RS1005097335 (1:209676835 G>A), RS1005935004 (1:209673871 G>C,T), RS1005971284 (1:209673814 T>C), RS1006400046 (1:209674127 C>T), RS1007168529 (1:209674737 C>A,T), RS1007614218 (1:209675520 G>A), RS1008779613 (1:209675502 C>T), RS1008832034 (1:209675739 C>G,T)

Disease associations

OMIM: gene MIM:614447 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

114 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	affects expression, decreases expression, increases expression	6
Valproic Acid	affects cotreatment, increases expression, decreases expression	6
Air Pollutants	affects expression, increases abundance, increases expression, decreases expression	5
Benzo(a)pyrene	increases expression, increases methylation, decreases expression	4
Estradiol	affects cotreatment, decreases expression, increases expression	4
Tretinoin	increases expression	4
Particulate Matter	decreases expression, affects cotreatment, increases abundance, increases expression	4
arsenite	increases reaction, decreases expression, increases methylation, affects binding	3
sodium arsenite	decreases expression, increases expression, affects acetylation, affects methylation	3
monomethylarsonous acid	affects acetylation, affects methylation, decreases expression, increases methylation	3
Cadmium	increases expression, increases methylation, decreases expression	3
Diethylstilbestrol	increases expression, decreases expression	3
Formaldehyde	decreases expression, increases expression	3
Progesterone	increases expression, affects cotreatment, decreases expression, affects expression, decreases reaction	3
Silicon Dioxide	increases expression	3
Smoke	increases abundance, increases expression, decreases expression	3
Cyclosporine	decreases expression, increases expression	3
Aflatoxin B1	affects expression, decreases expression	3
Genistein	affects expression, increases expression	3
perfluorooctanoic acid	affects expression, decreases reaction, increases expression	2
perfluorooctane sulfonic acid	decreases expression, increases expression	2
bisphenol S	increases expression	2
Rosiglitazone	decreases expression, increases expression	2
Acetaminophen	decreases expression	2
Calcitriol	increases expression	2
Dexamethasone	increases expression, affects cotreatment	2
Lipopolysaccharides	affects response to substance, increases expression	2
Oxygen	decreases expression, decreases reaction	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Tamoxifen	affects cotreatment, affects reaction, increases expression, affects expression	2

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.